KayakerBC

A company PP is only worth what investors are willing to pay based on what the real valuation is worth, and what I am saying is DM is hugely discounting Zenith shares based on what a properly BP managed company in this epigenetics space at this point of a clinically trialed  company should be at. The fact that Zenith is not trading on the Nasdaq is huge failure from not only DM but the BOD as well and maybe one of many reason why DM can only get $1.50 USD for PP plus the fact that ZHCLF is trading on the OTC at .25.  My hope is Zenith get sold soon so it get its real valuation . Hope is eternal